Cystic fibrosis drug combo put to the test with statins
NCT ID NCT07349394
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 1 study tested how a cystic fibrosis drug combo (vanzacaftor/tezacaftor/deutivacaftor) affects the body's processing of the statin rosuvastatin. 18 healthy adults took both medications to check for interactions and safety. The goal was to see if the drug combo changes rosuvastatin levels in the blood, which could guide future dosing for people with cystic fibrosis who also need statins.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Vanzacaftor/Tezacaftor/Deutivacaftor (a triple combination drug for cystic fibrosis)
- What this could lead to
- If successful, this study could help doctors understand how to safely combine this cystic fibrosis treatment with common statins like rosuvastatin.
- What could go wrong
- This is a very early, small study in healthy people, not patients. It only checks drug interactions, not whether the treatment works for cystic fibrosis.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
18 people
The number who actually took part.
- Started
-
Jan 2026
- Finished
-
Mar 2026
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 55 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Key Inclusion Criteria: * Body mass index (BMI) of 18.0 to 32.0 kilogram per meter square (Kg/m\^2), both inclusive * A total body weight greater than (\>)50 kg Key Exclusion Criteria: * History of febrile illness within 5 days before the first dose of study drug * Any condition possibly affecting drug absorption * Female participants who are pregnant, nursing, or planning to become pregnant during the study or within 90 days after the last dose of the study drug * Male participants with a female partner who is pregnant, nursing, or planning to become pregnant during the study or within 90 days after the last dose of the study drug Other protocol defined Inclusion/Exclusion criteria may apply.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cystic fibrosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Altasciences - Kansas City
Overland Park, Kansas, 66212, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Device-Preserved donor lungs boost transplant success?
- Can a simple questionnaire reveal why some cystic fibrosis patients skip physiotherapy?
- Cystic fibrosis diabetes: do gut hormones and genes hold the key?
- Can a special lung scan catch cystic fibrosis damage earlier than standard tests?
- Can a pill replace the liquid? testing a new form of cystic fibrosis drug
- Triple therapy under the microscope: does it transform cystic fibrosis care?